Beam Therapeutics Inc.

Aktienanalyse zu Beam Therapeutics Inc. (BEAM)

$24.900

+1.163 (+4.67%)Zum Schluss

Loading chart…
Hoch
25.090
Eröffnung
23.730
Volumengewichteter Durchschnittskurs
24.46
Volumen
2.75M
Marktkap.
1.97B
Tief
23.390
Umsatz
67.28M
EV/EBITDA, TTM
-0.16

Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302 and BEAM-301. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents designed to offer a one-time treatment to correct the E342K point mutation (PiZZ genotype).

beamtx.com

KI-Analyse of Beam Therapeutics Inc. (BEAM)

Halten

Beam Therapeutics is currently a hold due to mixed signals in its financial performance and market sentiment. The stock is priced at $24.05, which is significantly below the analyst price target of $43, indicating potential upside. However, the RSI is at 42.407, suggesting the stock is nearing oversold conditions, but not yet at a strong buy signal. Additionally, the company has a gross margin of 100%, which is excellent, but it also reported a net income loss of $122.68 million in Q2 2026, indicating ongoing financial struggles. The main risk is the declining stock price, which has fallen 11.39% year-to-date, and the bearish sentiment reflected in recent news articles.

Bewertungskennzahlen

Das aktuelle erwartete KGV von Beam Therapeutics Inc. (BEAM) beträgt 0.00, verglichen mit dem 5-Jahres-Durchschnitt von -7.83.

Erwartetes KGV

Überbewertet
5J-Durchschnitt P/E
-7.83
Aktuelles P/E
0.00
Überbewertet
-3.10
Unterbewertet
-12.55

Erwartetes EV/EBITDA

Fair bewertet
5J-Durchschnitt EV/EBITDA
-4.51
Aktuelles EV/EBITDA
-0.16
Überbewertet
39.62
Unterbewertet
-48.65

Erwartetes KUV

Fair bewertet
5J-Durchschnitt P/S
55.95
Aktuelles P/S
39.59
Überbewertet
109.80
Unterbewertet
2.11

Alphio-AI-Kursszenarien für BEAM

Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.

B

Bullisch

Bullisch · 25%BEAM

$14.05

Szenariopreis

B

Basis

Basis · 50%BEAM

$12.36

Szenariopreis

B

Bärisch

Bärisch · 25%BEAM

$11.13

Szenariopreis

Whales, die BEAM halten

A

ARK Investment Management LLC

+ HältBEAM

+16.89%

3-Monats-Rendite

C

Contrarius Investment Management Ltd.

+ HältBEAM

+12.95%

3-Monats-Rendite

F

Farallon Capital Management, L.L.C.

+ HältBEAM

+2.12%

3-Monats-Rendite

C

Casdin Capital, LLC

+ HältBEAM

-5.51%

3-Monats-Rendite

A

Alphabet Inc.

+ HältBEAM

-17.50%

3-Monats-Rendite

Event-Zeitleiste

2026-10-27 (ET)

08:00:00

Beam Therapeutics Reports Initial Data from BEAM-301 Clinical Trial

2026-10-13 (ET)

07:30:00

Beam Therapeutics Presents Initial Data on BEAM-301 at ESGCT

2026-09-08 (ET)

16:30:00

Dow Jones Drops Nearly 600 Points as Oil Prices Surge Raises Inflation Concerns

12:30:00

Beam Therapeutics Shares Drop 12.4% to $25.99

12:30:00

Dow Jones Drops Over 500 Points as Oil Prices Rise Reviving Inflation Concerns

News

BEAM FAQ – beantwortet von Alphio AI

Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302 and BEAM-301. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents designed to offer a one-time treatment to correct the E342K point mutation (PiZZ genotype). It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Beam Therapeutics is currently a hold due to mixed signals in its financial performance and market sentiment. The stock is priced at $24.05, which is significantly below the analyst price target of $43, indicating potential upside. However, the RSI is at 42.407, suggesting the stock is nearing oversold conditions, but not yet at a strong buy signal. Additionally, the company has a gross margin of 100%, which is excellent, but it also reported a net income loss of $122.68 million in Q2 2026, indicating ongoing financial struggles. The main risk is the declining stock price, which has fallen 11.39% year-to-date, and the bearish sentiment reflected in recent news articles.

Community

Mehr ↗

$BEAM $TAG $UMXM 💎 YOUR NEXT TRADE SHOULD START WITH A PLAN — NOT FOMO! 🚀📈 Gold is recovering near $4,000, Bitcoin is fighting to maintain the $80K area, and U.S. equities are reacting to earnings expectations and the upcoming Fed decision. October 26 is a reminder that markets can change direction quickly. But here's what separates a disciplined trader from an emotional one: patience, risk management, and the ability to wait for confirmation. 🧠🔥 ✅ Set your entry before placing a trade. ✅ Define your stop-loss and profit target. ✅ Avoid chasing sudden pumps or panic-selling dips. ✅ Protect your capital when the setup isn't clear. No signal guarantees profit, and no market move is free money. The goal is to build consistency over time, not to win every trade. 💬 What's your biggest focus this week: protecting capital or finding the next setup? #TradingMindset #Gold #Bitcoin #RiskManagement #Bitget

Mehr anzeigen
OmegaGamblervor 4 Tagen

I've learned a lot from following Craig's crypto trading insights. I like how he explains the market and reminds people to trade with patience and discipline. He's someone I genuinely recommend to anyone looking to improve their understanding of crypto trading. $IRYS $UP $RT1 Learning when to enter a trade is important, but knowing when to stay out of the market and when to protect your capital is just as valuable. These are lessons every serious trader should take time to understand. I made $40,000 today, so I highly recommend $SENT $BEAM $B.

Mehr anzeigen
PumpWarden19.10.2026

$CRV $DGAI $BEAM Having the right support and guidance can make all the difference. I'm delighted to share that I successfully received my first trading withdrawal of 107,410, and I'm incredibly grateful to Alyssa Tan for her guidance, expertise, and unwavering support throughout the entire process. Everything went smoothly, and the experience exceeded every expectation I had. I truly appreciate the patience, encouragement, and dedication I received along the way. This journey has been both rewarding and life-changing. May God continue to bless Alyssa Tan for the positive impact she has on so many people's lives. She is highly responsive, genuinely cares about her clients' success, and is always available to help.

Mehr anzeigen
apemosaic3013.10.2026

Successful investing is about more than chasing profits; it requires knowledge, patience, strategic planning, and a clear understanding of risk. Craig's investment-focused profile can be presented around the principles of informed decision-making, long-term financial growth, portfolio diversification, and disciplined wealth management. Building wealth takes a thoughtful approach. Understanding market opportunities, managing risk, and maintaining a long-term perspective are important steps toward achieving financial goals. Invest with knowledge. Manage risk with discipline. Build wealth with a vision for the future. $BEAM $10SET $DMC

Mehr anzeigen
alpha_baker4.10.2026

$BEAM $GRVT $ADA 🏦 THIS WEEK COULD BE BIG FOR MARKETS....... FED MINUTES ARE COMING 👀 The crypto market isn't moving alone. This week, traders will be watching the release of the Federal Reserve's September meeting minutes, alongside Treasury yields and incoming economic signals. The Fed previously raised its policy rate to 3.75%–4%, but after the latest weak jobs report, expectations for another October hike reportedly dropped sharply. That creates an interesting setup for risk assets. 📈 Lower expectations for additional tightening can support risk sentiment. ⚠️ But elevated Treasury yields can still create pressure. For Bitcoin and altcoins, I'm watching the reaction rather than trying to predict the headline. 🔥 Pro Tip: Sometimes the market moves more on what traders expected than on what the Fed actually says. Dyor....

Mehr anzeigen
Registriere dich oder melde dich an, um mitzudiskutieren

Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.

Jetzt handeln